Abstract
Utilizing medicinal chemistry design strategies such as benzo splitting and ring expansion, we converted PPARα/γ dual agonist 1 to selective PPARα agonists 19 and 20. Compounds 19 and 20 were 2- to 4-fold better than rosiglitazone at PPARγ receptor, with 80- to 100-fold PPARγ selectivity over PPARα receptor. X-ray cocrystal studies in PPARγ and modeling studies in PPARα give molecular insights for the improved PPARγ potency and selectivity for 19 when compared to 1.
Original language | English |
---|---|
Pages (from-to) | 2618-2622 |
Number of pages | 5 |
Journal | Journal of Medicinal Chemistry |
Volume | 52 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2009 Apr 23 |
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Drug Discovery